UBS AM
IMVT icon

UBS AM’s Immunovant IMVT Stock Holding History

UBS AM’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Sell
115,102
-26,626
-19% -$811K ﹤0.01% 1665
2026
Q1 		$3.52M Buy
141,728
+7,287
+5% +$189K ﹤0.01% 1751
2025
Q4 		$3.42M Buy
134,441
+27,217
+25% +$607K ﹤0.01% 1647
2025
Q3 		$1.73M Sell
107,224
-93,036
-46% -$1.51M ﹤0.01% 1816
2025
Q2 		$3.2M Buy
200,260
+60,169
+43% +$910K ﹤0.01% 1930
2025
Q1 		$2.39M Sell
140,091
-139,161
-50% -$2.91M ﹤0.01% 1900
2024
Q4 		$6.92M Sell
279,252
-31,578
-10% -$896K ﹤0.01% 1440
2024
Q3 		$8.86M Sell
310,830
-9,678
-3% -$285K ﹤0.01% 1291
2024
Q2 		$8.46M Buy
320,508
+114,477
+56% +$3.26M ﹤0.01% 1213
2024
Q1 		$6.66M Sell
206,031
-1,521
-0.7% -$55.5K ﹤0.01% 1144
2023
Q4 		$8.74M Buy
207,552
+124,636
+150% +$4.59M ﹤0.01% 1042
2023
Q3 		$3.18M Buy
82,916
+31,194
+60% +$705K ﹤0.01% 1400
2023
Q2 		$802K Hold
51,722
– – ﹤0.01% 2104
2023
Q1 		$802K Buy
51,722
+7,968
+18% +$138K ﹤0.01% 2104
2022
Q4 		$777K Buy
43,754
+6,409
+17% +$80.7K ﹤0.01% 1982
2022
Q3 		$208K Sell
37,345
-14,597
-28% -$71.4K ﹤0.01% 2599
2022
Q2 		$203K Hold
51,942
– – ﹤0.01% 2578
2022
Q1 		$286K Hold
51,942
– – ﹤0.01% 2610
2021
Q4 		$443K Hold
51,942
– – ﹤0.01% 2601
2021
Q3 		$451K Sell
51,942
-8,255
-14% -$74.5K ﹤0.01% 2537
2021
Q2 		$636K Buy
60,197
+16,650
+38% +$232K ﹤0.01% 2440
2021
Q1 		$698K Sell
43,547
-1,094
-2% -$28.8K ﹤0.01% 2256
2020
Q4 		$2.06M Buy
44,641
+24,641
+123% +$1.14M ﹤0.01% 1672
2020
Q3 		$704K Buy
20,000
+11,100
+125% +$334K ﹤0.01% 1977
2020
Q2 		$217K Buy
+8,900
New +$191K ﹤0.01% 2370

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's IMVT Position: Q2 2026 in Review

UBS AM reduced its Immunovant (IMVT) stake by 19% in Q2 2026, selling an estimated $811K and leaving 115,102 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

UBS AM first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.86M in Q3 2024. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • UBS AM held 115,102 shares of Immunovant worth $4.43M as of Q2 2026.
  • UBS AM sold 26,626 Immunovant shares in Q2 2026, an estimated $811K.
  • Immunovant made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1665 holding.
  • UBS AM first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • UBS AM's Immunovant position peaked at $8.86M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.